Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sulfasalazine
Drug ID BADD_D02093
Description A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
Indications and Usage For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent.
Marketing Status Prescription; Discontinued
ATC Code A07EC01
DrugBank ID DB00795
KEGG ID D00448
MeSH ID D012460
PubChem ID 5339
TTD Drug ID D02ZTJ
NDC Product Code 68071-4215; 23155-019; 70518-1829; 50090-0086; 49964-0018; 43353-495; 63629-5688; 70518-0185; 51927-0054; 51927-0081; 0591-0796; 0013-0101; 59762-0104; 38779-0176; 0013-0102; 50268-730; 59116-0632; 62705-0222; 62991-2704; 57294-021; 59116-0631; 71610-577; 59762-5000; 59116-0633; 59116-0630; 62135-960; 51552-1044; 50090-2013; 49452-7523; 68022-7065; 70518-2342
Synonyms Sulfasalazine | Salicylazosulfapyridine | Sulphasalazine | Salazosulfapyridine | Pyralin EN | Azulfadine | Azulfidine EN | Azulfidine | Asulfidine | Colo-Pleon | Colo Pleon | Pleon | Ulcol | Sulfasalazin medac | Sulfasalazin-Heyl | Sulfasalazin Heyl | Sulfasalazine FNA | Ucine | Salazopyrin | ratio-Sulfasalazine | ratio Sulfasalazine
Chemical Information
Molecular Formula C18H14N4O5S
CAS Registry Number 599-79-1
SMILES C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Leukopenias NECCytochrome P450 1A2P05177Not Available11600468; 11856081; 11600469
VasculitisMyeloperoxidaseP05164T234717913504; 7913503; 8102951; 7914458; 8624621; 7869327; 7835022; 8095074; 8624617
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Intestinal stenosis07.13.01.0030.001382%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.003454%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Joint contracture15.01.08.0010.001382%Not Available
Joint stiffness15.01.02.0030.002763%Not Available
Joint swelling15.01.02.0040.008980%Not Available
Kawasaki's disease11.07.01.007; 24.05.01.003; 10.02.02.009--Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.001382%
Leukocytosis01.02.01.0020.002763%
Leukopenia01.02.02.0010.007598%Not Available
Lichen planus23.03.08.001--Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.003454%Not Available
Lipase increased13.05.01.0030.005526%
Liver disorder09.01.08.0010.005526%Not Available
Liver function test abnormal13.03.01.0130.003454%Not Available
Liver transplant25.09.02.001--Not Available
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.0010.005526%Not Available
Lung infiltration22.01.02.0040.001382%Not Available
Lymphadenopathy01.09.01.0020.007598%Not Available
Lymphoma16.20.01.001; 01.12.01.0010.000541%Not Available
Lymphopenia01.02.02.0020.002072%Not Available
Macular degeneration06.09.03.0010.002072%Not Available
Malabsorption14.02.01.004; 07.17.01.001--
Malaise08.01.01.0030.020032%
Melaena24.07.02.013; 07.12.02.004--Not Available
Meningitis17.06.03.001; 11.01.03.0010.001382%
Meningitis aseptic17.06.03.002; 11.01.03.0020.001382%Not Available
Metabolic acidosis14.01.01.003--Not Available
Methaemoglobinaemia01.05.01.002--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 15 Pages